MedTrace Logo

Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy

NCT06204406 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2024-01-12

No results posted yet for this study

Summary

Upper tract urothelial carcinoma (UTUC) is a rare malignant disease which accounts for 5-10% of urothelial carcinoma in the western world and 9%-30% in China. About two thirds of patients have muscle invasive disease at diagnosis. Those patients usually have poor prognosis. The 5 year cancer specific survival is \<50% for pT2/T3 and \<10% for pT4. Radical nephroureterectomy is the standardized treatment for non-metastatic high risk UTUC. However, about half patients may suffer from impaired renal function after nephroureterectomy. On the other hand, kidney sparing surgery can avoid renal function impairment, but the therapy is only recommended for few patients with low-risk disease. The treatment for urothelial carcinoma has changed rapidly in the past few years. Immune checkpoint inhibitors and novel agents such as ADCs have shown promising therapeutic effect and were approved for patients with metastatic UTUC. Meanwhile, a recent study shows that patients with high-risk disease can also receive kidney sparing surgery without compromising cancer specific survival and overall survival. This prospective, observational study aims to evaluate the prognosis of contemporary kidney sparing surgery in patients with UTUC with or without perioperative therapy in the real world.

Conditions

  • Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy

Interventions

OTHER

Observational

This is a prospective observational study with observation only and no intervention

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Tianjin Medical University Second Hospital

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER

  • The First Affiliated Hospital of University of Science and Technology of China

    collaborator OTHER

  • The Second Hospital of Anhui Medical University

    collaborator OTHER

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • RenJi Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-23
Primary Completion
2028-07-01
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06204406 on ClinicalTrials.gov